Latest / Houston's Morning News on KTRH / Dr. Joe Galati - KTRH Medical Analyst Joins Houston's Morning News
Transcript
- 0:00Speaker 1: 5.52 now.
- 0:01Speaker 2: You're in Houston's Morning News. What's in your medicine cabinet?
- 0:04Speaker 2: I had to take a picture because I have an
- 0:06Speaker 2: appointment today with my cardiologist. I took a picture of
- 0:09Speaker 2: five different bottles of things I'm taking. And I was wondering,
- 0:13Speaker 2: I wonder how many of them are actually made here
- 0:16Speaker 2: in the United States versus a foreign country, most specifically China.
- 0:21Speaker 1: Dr.
- 0:21Speaker 2: Joe Gulati joins us, KTRH medical analyst. I think we
- 0:25Speaker 2: all know that we need to be making our own
- 0:26Speaker 2: medicines for national security purposes, Dr. Gulati, but How many
- 0:29Speaker 2: of our medicines are still coming from a place like China?
- 0:33Speaker 1: Well, let's put it this way. Turn it the other
- 0:36Speaker 1: way around.
- 0:36Speaker 3: We're only making around 4% of the components for things
- 0:40Speaker 3: like antibiotics.
- 0:41Speaker 1: And so I would say.
- 0:43Speaker 3: Over the past 20 years or so, there was just
- 0:46Speaker 3: a tremendous shift where everything was moved offshore, where we
- 0:51Speaker 3: are truly, and you said it earlier, there is a
- 0:53Speaker 3: chokehold here.
- 0:54Speaker 1: This is a national security risk. And think about it,
- 0:59Speaker 1: it's almost as if we.
- 1:01Speaker 3: Didn't remember what happened with COVID where so much of
- 1:06Speaker 3: our supply chain was offshore and we had challenges getting
- 1:13Speaker 3: what we needed.
- 1:14Speaker 1: And it really makes no sense.
- 1:16Speaker 3: I would think that this would be really a priority
- 1:20Speaker 3: to create these facilities that are creating the chemical foundation
- 1:26Speaker 3: for the drugs we need.
- 1:28Speaker 1: It would be a boom for employment.
- 1:30Speaker 3: We have the engineering, we have the technology, we have
- 1:33Speaker 3: the chemistry know-how.
- 1:35Speaker 1: To do this all.
- 1:36Speaker 3: And so I don't understand how this all happened over
- 1:40Speaker 3: the past 20, 30 years.
- 1:42Speaker 2: I'm guessing it happened because it's cheaper to produce them overseas.
- 1:45Speaker 2: But are there any medicines that are produced in places
- 1:48Speaker 2: like China? Because they're the ones that have the chemicals
- 1:50Speaker 2: and the ingredients and we don't.
- 1:53Speaker 1: Well, you know, that I do not know for sure.
- 1:56Speaker 3: I would say most of the mainstream medications that are available,
- 2:00Speaker 3: I don't think it's something unique that it's only found
- 2:03Speaker 3: in the soil.
- 2:06Speaker 1: In China, or they're the only ones that have the
- 2:08Speaker 1: know-how to do it. I think you're right.
- 2:09Speaker 3: I think it was a decision that it was financially
- 2:13Speaker 3: cheaper to move it over there. And maybe 20, 25
- 2:17Speaker 3: years ago, it was a good idea. But when you're
- 2:19Speaker 3: dealing with people that at any moment could shut this off,
- 2:23Speaker 3: and really just turn us into a puppet, it really
- 2:28Speaker 3: makes no sense. And with all that we've been trying
- 2:32Speaker 3: to do to you know, become independent to all of
- 2:36Speaker 3: these countries around the world. I think this is a very,
- 2:39Speaker 3: very big piece of the puzzle that we have to
- 2:41Speaker 3: work on.
- 2:41Speaker 2: Not that you have an inside link with anybody in
- 2:45Speaker 2: big pharma, Dr. Gulati, but I'm guessing the truth be
- 2:49Speaker 2: told with them, again, I'm sure it's all about money.
- 2:52Speaker 2: By the same token, it's not like we don't pay
- 2:54Speaker 2: enough for drugs here in the United States. It's not
- 2:58Speaker 2: like they can't afford to produce them here and still
- 3:00Speaker 2: make a profit.
- 3:01Speaker 3: Well, you know, you think about it and you say, okay,
- 3:03Speaker 3: it's going to China because they've got somebody working for,
- 3:06Speaker 3: you know, 50 cents an hour. But that savings is
- 3:09Speaker 3: not translated to the cost at the pharmacy. So you're
- 3:13Speaker 3: right about that. So there's something really sinister sort of
- 3:20Speaker 3: is going on here where I think– So the idea
- 3:23Speaker 3: that it's cheaper, but yet the consumer is still paying
- 3:25Speaker 3: a heck of a lot of money doesn't make sense.
- 3:28Speaker 3: And so you would think that we'd still be able
- 3:31Speaker 3: to manufacture it here at higher wages for the people
- 3:35Speaker 3: that would do it here. And you could almost say
- 3:38Speaker 3: it would be break even here, but it's not. It's
- 3:42Speaker 3: a complicated story, but I think despite that, it is
- 3:47Speaker 3: so important that we start making these products here, similar
- 3:51Speaker 3: to making the chips that President Trump started off with,
- 3:54Speaker 3: being dependent on other countries for the vital infrastructure that
- 3:58Speaker 3: we need for all of that.
- 3:59Speaker 1: I think the drugs are the very next thing that
- 4:01Speaker 1: we have to really attack.
- 4:03Speaker 2: Let me ask you, too, while I have you here,
- 4:04Speaker 2: there's been so many stories about GLP-1s since they've come out.
- 4:08Speaker 2: And it seems like we all know somebody who's taking
- 4:10Speaker 2: a GLP-1. And for the most part, they seem to
- 4:12Speaker 2: be highly beneficial. At least I have not seen any
- 4:15Speaker 2: stories that indicate that they are not. They are sometimes
- 4:18Speaker 2: in short supply. They are very, very expensive. So there
- 4:22Speaker 2: are a lot of people who can't afford to get them.
- 4:24Speaker 2: But what is your overall opinion of GLP-1s?
- 4:28Speaker 3: It really is somewhat of a miracle because you look
- 4:32Speaker 3: at and really a week does not go by where
- 4:34Speaker 3: there is not a new beneficial effect. Certainly in, you know,
- 4:40Speaker 3: certainly just the last two or three years, we have
- 4:42Speaker 3: found that not only are you losing weight, your diabetes
- 4:45Speaker 3: is getting under control, but now they're showing that there
- 4:49Speaker 3: is tremendous cardiovascular benefit, reduced heart attack and stroke and
- 4:54Speaker 3: increased longevity.
- 4:56Speaker 1: For me personally, in my line of work, we're.
- 5:00Speaker 3: Using it for people that have fatty liver, so we're
- 5:02Speaker 3: reducing the risk of people developing cirrhosis and liver cancer
- 5:06Speaker 3: needing liver transplant.
- 5:07Speaker 1: There is a lot of work that's.
- 5:09Speaker 3: Being done in the addiction field space with alcohol or
- 5:13Speaker 3: other substance abuse, where GLPs, because they're working in the
- 5:17Speaker 3: brain with these receptors, it's cutting down on the craving.
- 5:21Speaker 3: And so it's not so much that these are the
- 5:24Speaker 3: miracle drugs that are the panacea for all these problems,
- 5:28Speaker 3: but they are tremendously beneficial to And, again, I think
- 5:33Speaker 3: as the usage goes up in the production, you'd like
- 5:36Speaker 3: to think that the cost of these are going to
- 5:39Speaker 3: come down and, you know, be available to more people.
- 5:42Speaker 1: All right, Dr. Gulati, always good to hear from you, sir.
- 5:45Speaker 1: Thank you. Be healthy.
- 5:46Speaker 2: That's KTRH Medical Analyst, Dr.
- 5:48Speaker 1: Joe Gulati. It's 557.